COVID-19 / Paid-only Developing Countries Mean Business on Equity Provisions in Pandemic Agreement. Will it Count? Newsletter Edition #65 [Treaty Talks] By Priti Patnaik / 20 Feb 2024
COVID-19 / Paid-only Will Countries Begin Text-Based Negotiations for a Pandemic Agreement Next Week: The What, How and Why Not? [PRIMER INB8] Newsletter Edition #64 [Treaty Talks] By Priti Patnaik / 16 Feb 2024
COVID-19 / Paid-only Equity Provisions in the IHR: A Race Against Time Newsletter Edition #63 [Treaty Talks] By Priti Patnaik / 10 Feb 2024
COVID-19 / Paid-only Developing Countries Seek to Retain Equity Provisions in the Amendments to the IHR [WGIHR7 Update] Newsletter Edition #62 [Treaty Talks] By Priti Patnaik / 7 Feb 2024
COVID-19 WHO DG's Marked Shift on Intellectual Property: Cautions Against Undermining IP on Access to COVID-19 Tests & Treatments at WTO. Implications for "Equity" in Current Negotiations Newsletter Edition #61 [Treaty Talks] By Priti Patnaik / 20 Dec 2023
Access to Medicines Listen Now: The Geneva Health Files Interview with Fatima Hassan Podcast: Episode 07 [The Geneva Health Files Podcast] By Priti Patnaik / 15 Dec 2023
Access to Medicines Pathogen Access & Benefit Sharing System: A Key to Operationalize Equity in Pandemic Preparedness & Response [GUEST ESSAY] Newsletter Edition #58 [Treaty Talks] By Priti Patnaik / 6 Dec 2023
Access to Medicines EXCLUSIVE: Did Some Developed Countries Oust Africa Group’s Key Negotiator, a Forceful Voice on Equity Provisions in INB-IHR Negotiations? Newsletter Edition #57 [Treaty Talks] By Priti Patnaik / 1 Dec 2023
Access to Medicines Want to Boost Regional Vaccine Manufacturing? Let Countries Prioritize, Ensure Tech Transfer Newsletter Edition #56 [Treaty Talks] By Priti Patnaik / 22 Nov 2023
Access to Medicines A Little Fairer is Not Good Enough: Why ABS Will NOT Ensure Equity [GUEST ESSAY] Newsletter Edition #55 [Treaty Talks] By Priti Patnaik / 15 Nov 2023
Pricing Johnson & Johnson’s Patenting & Pricing Strategy for TB Medicine Bedaquiline: A Cautionary Tale for New TB Medicines [GUEST ESSAY] Newsletter Edition #200 [The Curated Primer] By Priti Patnaik / 6 Oct 2023
![Will Countries Begin Text-Based Negotiations for a Pandemic Agreement Next Week: The What, How and Why Not? [PRIMER INB8]](/content/images/size/w960/format/webp/substack-post-media-s3-amazonaws-com/public/images/f78e6235-5355-47ec-8d38-d55201f1238c_4000x6000.jpg)
![Developing Countries Seek to Retain Equity Provisions in the Amendments to the IHR [WGIHR7 Update]](/content/images/size/w960/format/webp/substack-post-media-s3-amazonaws-com/public/images/ca1d73e4-74bf-4802-85a7-eb88f77c68d4_5832x4374.jpg)
![Pathogen Access & Benefit Sharing System: A Key to Operationalize Equity in Pandemic Preparedness & Response [GUEST ESSAY]](/content/images/size/w960/format/webp/substack-post-media-s3-amazonaws-com/public/images/e209e792-791e-4fde-88d6-e3e6d279d48c_5746x3830.jpg)
![A Little Fairer is Not Good Enough: Why ABS Will NOT Ensure Equity [GUEST ESSAY]](/content/images/size/w960/format/webp/substack-post-media-s3-amazonaws-com/public/images/c194a843-3625-4993-b6de-3b4b4e4c5f51_5616x3744.jpg)
![Johnson & Johnson’s Patenting & Pricing Strategy for TB Medicine Bedaquiline: A Cautionary Tale for New TB Medicines [GUEST ESSAY]](/content/images/size/w960/format/webp/substack-post-media-s3-amazonaws-com/public/images/f36f3802-bd56-4ad0-bc72-fe2fe0929e3d_4032x3024.jpg)